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Abstract
This chapter discusses the capabilities of positron emission tomography (PET) imaging
for the diagnosis of Alzheimer’s disease (AD) with deposition of amyloid-β (Aβ). We
conducted a PET scan using 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-
pyridin-3-ylmethoxy}-2H-pyridazin-3-one  (18F-BCPP-EF),  a  novel  PET  probe  for
mitochondrial complex I (MC-I) activity, in young and aged monkeys to demonstrate
the normal aging effects on MC-I activity in the brain. The results revealed an age-related
impairment of MC-I activity in the brain. Then, we conducted PET scan using 11C-PIB
to detect the Aβ deposition in the some parts, not all, of the brains of some part of aged
monkeys. For further assessments, PET scans using 11C-PIB for Aβ, 11C-DPA-713 for
inflammation, 18F-fluoro-2-deoxy-D-glucose (18F-FDG) for regional cerebral metabolic
rate of glucose (rCMRglc), and 18F-BCPP-EF for MC-I were performed in aged animals.
When 18F-BCPP-EF uptake is plotted against 11C-PIB uptake in the cerebral cortical
regions, it showed a significant negative correlation between them. Plotting of 11C-
DPA-713 uptake against 11C-PIB resulted in a significant positive correlation. In contrast,
plotting of rCMRglc against 11C-PIB did not reach a statistically significant level. Taken
together,  these  results  strongly suggested that  18F-BCPP-EF could discriminate  the
neuronally damaged areas with neuroinflammation where 18F-FDG could not, owing
to its high uptake into the activated microglia.
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1. Introduction
Alzheimer’s disease (AD) is neuropathologically characterized by the presence of neurofibril‐
lary tangles with the deposition of hyperphosphorylated tau protein inside nerve cells and
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
senile plaques with extracellular aggregation of amyloid-β (Aβ) protein, and the imaging of
tau and Aβ is expected to provide quantitative information noninvasively for the diagnosis of
AD.  Pathological  aging  processes  are  thought  to  be  a  degenerative  process  caused  by
accumulated damages, which leads to cellular dysfunction, tissue failure, and death, result‐
ing in detectable changes in brain structure and function. Modern in vivo imaging techni‐
ques, such as X-ray computed tomography (X-CT), magnetic resonance imaging (MRI), and
positron emission tomography (PET), provide useful ways to examine these alterations and
to separate normal age-related changes from pathological states. Because functional distur‐
bances precede structural changes determined by X-CT or MRI, the in vivo imaging obtained
with PET may be abnormal, whereas the brain anatomy appears normal.
One trend is to apply target-specific PET probes for quantitative imaging of the specific
neurological target molecules related to diseases, such as the dopaminergic system for
schizophrenia [1] and Parkinson’s disease (PD) [2], the serotonergic system for depression [3],
and the cholinergic system for AD-type dementia [4]. Another trend is to measure more general
indices for the pathophysiological abnormalities in diseases. To diagnose these diseases and
to assess the treatment efficacy of developing drug candidates noninvasively with PET, we
have anticipated PET probes that can provide general indices of brain function, such as regional
cerebral blood flow (rCBF) and regional cerebral metabolic rate of oxygen (rCMRO2), both of
which have been recognized to be the gold standard indices for cerebral functions [5]. Other
useful indicators are the regional cerebral metabolic rate of glucose (rCMRglc) assessed with
18F-fluoro-2-deoxy-D-glucose (18F-FDG; Figure 1C) [6]. PET using 18F-FDG is a well-establish‐
ed technique for the quantitative imaging of brain function in the living brain. Some re‐
search demonstrated that 18F-FDG could predict an onset of AD. However, as demonstrated
in the brains of rat and monkey ischemic models [7, 8], the unexpectedly high uptake of 18F-
FDG in damaged areas suggested that 18F-FDG was taken up into not only normal tissues but
also inflammatory regions with microglial activation, which hampers the accurate diagnosis
of brain function using 18F-FDG.
Figure 1. PET probes used: (A) 11C-PIB for Aβ, (B) 11C-DPA-713 for TSPO, (C) 18F-FDG for rCMRglc, (D) 11C-(+)-3-MPB
for mAChR, (E) 11C-(R)-MeQAA for α7-nAChR, and (F) 18F-BCPP-EF for MC-I.
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Several hypotheses of aging at the molecular level, such as shortening of telomerase, DNA
methylation, reactive oxygen species (ROS) generation, and mitochondrial abnormalities, have
been proposed. Among these, the “mitochondrial free radical theory of aging” has been
highlighted [9]. In mammalian cells, the electron transport chain in mitochondria consists of
five complexes from I to V, and the main role of mitochondria was recognized to be energy
transduction of ATP. Their dysfunction was thought to be limited to ATP deficiency result‐
ing in necrotic cell death; however, the mechanisms of cell death have been found to include
mitochondrial contribution to oxidative stress and apoptosis [10]. Previous studies demon‐
strated an age-related increase in ROS production using rat brain homogenates [11], cortical
slices [12], or synaptosomes [13]. Furthermore, mitochondrial dysfunction contributes to the
pathophysiology of acute and chronic neurodegenerative disorders [14].
In the present chapter, the capability of assessment of mitochondrial complex I (MC-I) activity
is introduced for detection of neurodegenerative damage associated with Aβ deposition. We
recently developed and evaluated 18F-2-tert-butyl-4-chloro-5-{6-[2-(2-fluoroethoxy)-ethoxy]-
pyridin-3-ylmethoxy}-2H-pyridazin-3-one (18F-BCPP-EF), a novel PET probe for MC-I
activity (Figure 1E) [15]. The translational research has been conducted using an animal PET
to assess the aging as well as Aβ deposition effects on MC-I activity in the living brains of
young (3–5 years old, corresponding to high-teens in humans) and aged (20–24 years old,
corresponding to 75 years old and more) male monkeys [16, 17].
2. Aging and cholinergic neuronal system
There have been a number of reports on age-related alterations in neurochemical and
neurophysiological functions in the brain, associated with changes in the neurotransmitter
synthesis in presynaptic neurons, release into synaptic cleft, reuptake availability, binding to
receptors, and signal transduction, all of which are related to the declines of specific motor,
cognitive and emotional functions in primates. Among the variety of neurotransmitter
receptors, we focused on the effects of aging process on cholinergic receptors, which had
previously assessed in the postmortem primate brain tissues [18].
2.1. Aging effects on muscarinic cholinergic receptor function
The cholinergic receptor (AChR) population is divided into muscarinic (mAChR) and
nicotinic (nAChR) subclasses in the central nervous system (CNS), and the CNS mAChR
system plays an important role in memory and cognitive functions. AD is neuropathological‐
ly characterized by the presence of neurofibrillary tangles with the deposition of Hyperphos‐
phorylated tau protein inside nerve cells and senile plaques with extracellular aggregation of
Aβ protein [19, 20]. Accompanied with tau and Aβ depositions, loss of cholinergic neurons in
the forebrain, reduced cholinergic activity in the hippocampus and cortical loss of choline
acetyltransferase, and reduced central mAChR binding have been observed in the brain of AD
patients [21]. The severity of these cholinergic abnormalities is closely correlated with the
degree of memory impairment in aged monkeys [22] and dementia patients [21].
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Several antagonist-based 11C-labeled PET probes for imaging mAChR have been developed
and attempted to determine quantitatively the age-related alterations of mAChR in the living
brain using 11C-benztropine [23], N-11C-methyl-4-piperidyl benzilate (11C-4-MPB) [24], and 11C-
tropanyl benzilate (TBZ) [25]. These PET probes for mAChR, however, showed relatively low
uptake to the brain and also slow dissociation rates from mAChR, which may limit the
estimation of the density of binding sites in vivo [26]. To solve these problems, we proposed a
novel mAChR probe, N-11C-methyl-3-piperidyl benzilate (11C-3-MPB) (Figure 1D) [27, 28], and
assessed the aging effects on mAChR binding in comparison to young and aged monkeys [29].
11C-(+)3-MPB was labeled by N-methylation of respective nor-compound with 11C-methyl
iodide converted from 11C-CO2 by LiAlH4 reduction followed by reaction with HI [27, 28]. A
monkey (Macaca mulatta) was seated on a monkey chair under conscious condition and fixed
with stereotactic coordinates under conscious state [30]. For the kinetic analysis of 11C-(+)3-
MPB binding, arterial blood sampling was conducted to determine the input function using
metabolic profile in plasma. The PET data obtained were reconstructed by the filtered back-
projection (FBP) method. Volumes of interest (VOIs) in brain regions were drawn manually
on the MRI, and VOIs of MRI were superimposed on the coregistered PET images to meas‐
ure the time activity curves (TACs) of each PET probe for kinetic analyses using Logan
graphical analysis with metabolite-corrected plasma input in the living brain [31].
The TACs of 11C-(+)3-MPB in the frontal, temporal, and occipital cortices reached their peaks
40 min after injection, whereas the striatal and hippocampal regions reached peak values 60
Figure 2. MRI and PET images of 11C-(+)3-MPB in the young and aged monkey brains (M. mulatta). PET data were col‐
lected in the conscious state with a high-resolution PET scanner. Each PET image was generated by summation of im‐
age data from 60 to 91 min post-injection. The stereotactic coordinates of PET and MRI were adjusted based on the
orbitomeatal (OM) line.
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min after injection [28]. In aged monkeys, the TACs of 11C-(+)3-MPB in regions rich in mAChR
peaked at earlier time points, with faster elimination rates than those in young monkeys. As
a result of Logan graphical analysis using metabolite-corrected plasma input, significant age-
related alterations of the in vivo binding of 11C-(+)3-MPB were observed in the temporal and
frontal cortices and the striatum (Figure 2). Aged animals showed the age-related reduction
of the maximum number of binding sites (Bmax) of mAChR, whereas there were no age-related
alterations of the affinity (1/Kd) of mAChR [29].
2.2. Aging effects on nicotinic cholinergic receptor function
The CNS AChR systems, classified into mAChR and nAChR, play an important role in memory
and cognitive functions. In the last two decades, 17 different nAChR subunits (α1–α10, β1–
β4,γ, δ and ε) have been cloned, and the prominent nAChRs are the α4β2 heteromeric and α7
homomeric subtypes in the brain [32]. Among them, because α7 has high permeability for Ca2+,
it can be assumed that, in addition to the ionotropic function induced by membrane depola‐
rization, α7-nAChR is associated with metabotropic activity coupled to Ca2+-regulated second-
messenger signaling required for the modulation of neuron excitability, neurotransmitter
release, induction of long-term potentiation (LTP), and cognitive-associated processing of
learning and memory. In addition, α7-nAChR may contribute to neuroprotection by modu‐
lating the neurotrophic system crucial for the maintenance of cholinergic neuron integrity and
also by stimulating signal transduction pathways that support neuron survival [32].
A PET study indicated that decreases in 11C-nicotine brain uptake were significantly correlat‐
ed with cognitive deficits in AD patients [33]; however, nAChR deficits in the different types
of dementia are assumed to be reflected by subtype and region specificity. For the noninva‐
sive imaging of α7-nAChR with more subtype specificity, several 11C-labeled PET probes have
been developed and evaluated, including 11C-CHIBA-1001, 11C-A-582941, and 11C-A-844606
[34]. However, because of low brain uptake, high nonspecific binding, and/or low selectivity
to α7-nAChR against 5-HT3R, almost none of these PET probes have demonstrated clinically
useful specific binding to α7-nAChR in nonhuman primate brain. Because we recently
developed novel PET probes for α7-nAChR, (R)-2-[11C]methylamino-benzoic acid 1-aza-
bicycle[2.2.2]oct-3-yl ester [11C-(R)-MeQAA; Figure 1E] [35], the aging effects on α7-nAChR
binding was assessed using 11C-(R)-MeQAA in comparison to young and aged monkeys [36].
11C-(R)-MeQAA was labeled by N-methylation of respective nor-compounds [(R)-BH3QAA]
with 11C-methyl triflate prepared from 11C-methyl iodide through a glass column containing
silver triflate [35]. PET measurements of conscious monkeys were conducted as described in
Section 2.2 with arterial blood sampling for plasma metabolic analysis followed by PET image
reconstruction and TAC acquisition in the VOIs for kinetic analyses. The values of nondis‐
placeable binding potential (BPND) were evaluated by two-compartment models (2-TC)
analysis using the metabolite-corrected plasma input [37] and simplified reference tissue
model (SRTM) analysis using the TAC in the cerebellum as an indirect input function [38].
11C-(R)-MeQAA images in the brain of young normal monkeys, showing high and heteroge‐
neous uptake of [11C](R)-MeQAA into the brain, were determined between 60 and 90 min after
the bolus injection. The uptake of radioactivity was high in the thalamus and striatum,
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intermediate in the hippocampus, frontal, temporal, and occipital cortices, and low in the
cerebellum [35, 36]. The uptake of 11C-(R)-MeQAA was significantly higher than that of 11C-(S)-
MeQAA in the thalamus, hippocampus, and cortical regions, and the specific binding of 11C-
(R)-MeQAA was inhibited by the preadministration of SSR180711, an α7-nAChR partial
agonist [35]. In contrast, the uptake of 11C-(R)-MeQAA into the cerebellum of monkeys was
not affected by SSR180711 [35], suggesting that the cerebellum could be applicable for the
reference region for the quantitative analysis of 11C-(R)-MeQAA binding in the living brain.
The clearance rate of 11C-(R)-MeQAA in plasma was rapid and relatively stable in plasma. To
determine the practicality of the simplified analytical method of 11C-(R)-MeQAA with SRTM
to calculate the BPND using the TAC in the cerebellum as an indirect input function, we verified
it by correlation analyses with 2-TC-BPND values calculated using the metabolite-corrected
plasma input. Because of a good correlation between 2-TC and SRTM analyses, 11C-(R)-
MeQAA binding to α7-nAChR in young and aged monkey brain was determined as the SRTM-
BPND values without arterial blood sampling to avoid excessive stress on aged animals. When
determining the aging effects on 11C-(R)-MeQAA binding, all regions, except the occipital
cortex, revealed no significant differences in the BPND values of 11C-(R)-MeQAA in the brains
of aged and young animals [36]. Although human aging is known to preferentially affect the
rCMRglc in the frontal and temporal lobes, our previous studies reported that the occipital
cortex showed the most profound reductions of CBF [39], rCMRglc [39], and MC-I [16] in aged
monkeys. Because the differences in cortical activity between monkey and human reflect the
evolutionary significance of their frontal cortex, the most marked age-related alterations of
α7-nAChR activity would be determined in regions such as the frontal cortex, not in the
occipital cortex, in humans. These results apparently revealed that aging effects were much
less on α7-nAChR compared to mAChR in the living brain.
3. Aging and MC-I activity
Mitochondria are called ”cellular power plants“ because they generate most of the ATP used
as a source of chemical energy. In mammalian cells, the electron transport chain in mitochon‐
dria consists of five complexes from I to V, and complex I (MC-I; NADH-ubiquinone oxidor‐
eductase, EC 1.6.5.3) is the first and rate-limiting step of the overall respiratory activity and
oxidative phosphorylation under physiological conditions. Glucose is converted to pyruvate
followed by transformation into acetyl-CoA by pyruvate dehydrogenase (PDH) in the
mitochondria, which is subsequently fed into the tricarboxylic acid (TCA) cycle, ultimately
producing ATP via the electron transport system and oxidative phosphorylation (which is
indispensable for cell survival). Mitochondrial dysfunction contributes to the pathophysiolo‐
gy of neurodegenerative diseases [40], some part of which has been considered to relate to the
fact that mitochondria are the main intracellular source of ROS in cells and also the main target
of ROS-mediated damage. Noninvasive assessment of living brain could be useful for the
diagnostic, prognostic, and treatment monitoring of neurodegenerative diseases related to
impaired MC-I function; however, no proper PET probes for MC-I imaging in the brain have
been developed prior to those that we have recently described [15].
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3.1. Development of PET probe for MC-I imaging
As PET probe for MC-I imaging, BMS-747158-01 showed inhibitory activity on MC-I func‐
tion by binding to MC-I, and its F-18 derivative 18F-BMS-747158-01 was originally developed
as a myocardial perfusion imaging agent [41]. However, we also realized that 18F-
BMS-747158-01 revealed relatively high nonspecific binding in the brain based on the lower
degree of inhibition with rotenone, a specific MC-I inhibitor, in both in vitro and in vivo
assessments [7, 8]. To solve the problem, we redesigned to modify the chemical structure of
18F-BMS-747158-01 to induce lower lipophilicity and lower affinity [15, 42]. We recently
developed a novel PET probe, 18F-BCPP-EF, and evaluated its properties in the in vitro and in
vivo assessments [7, 8, 15, 16].
For the analysis of the affinity of 18F-BCPP-EF, an in vitro binding assay was conducted using
3H-dihydrorotenone and bovine cardiomyocyte submitochondrial particles (SMP) to deter‐
mine the 50% inhibition (IC50) values, which were converted to the inhibition constant (Ki). 18F-
BCPP-EF was radiolabeled by the nucleophilic 18F-fluorination of the corresponding tosylate
precursor, toluene-4-sulfonic acid 2-{2-[5-(1-tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyrida‐
zin-4-yloxymethyl)-pyridin-2-yloxy]-ethoxy}-ethyl ester [15]. For the assessment of binding
specificity of the PET probe to MC-I, vehicle or rotenone, a specific MC-I inhibitor, at a dose
of 0.1 mg/kg was infused to anesthetised rats or conscious monkeys through a vein for 1 h,
and then 18F-BCPP-EF was injected as a bolus for PET measurement. PET measurements of
young monkeys (3–5 years old) were conducted under conscious state as described in
Section 2.2 with arterial blood sampling for plasma metabolic analysis followed by PET image
reconstruction and TAC acquisition in the VOIs aided by MRI of individual animals for kinetic
analyses [16, 17]. The total distribution volume (DV) values were evaluated by Logan plot
graphical analysis using the metabolite-corrected plasma input [33].
18F-BCPP-EF showed the lower affinity (Ki=2.31 nM) with lower lipophilicity (logD7.4=3.03) for
MC-I of bovine cardiomyocytes than that of BMS-747158-01 (Ki=0.95 nM, logD7.4=3.69). In PET
study in rats, the radioactivity level of 18F-BCPP-EF in the brain showed rapid uptake and
gradual decrease with time just after the injection under vehicle condition. In the heart, 18F-
BCPP-EF exhibited slow accumulation up to 30 min after the injection followed by a slight
washout. With preadministration of rotenone, although a dose escalation study of rotenone
was impossible because of its lethal effects on cardiac function, a significant reduction of 18F-
BCPP-EF uptake was observed in the brain and heart, even at a relatively low dose of 0.1 mg/
kg/h. 18F-BMS-747158-01 showed a tendency of decreased brain uptake with rotenone infusion
but was not fully inhibited [7].
In the conscious monkey brain, TACs of 18F-BCPP-EF peaked between 10 and 20 min after the
injection, except in the occipital cortex (40 min), followed by the gradual elimination with time.
With preadministration of rotenone, a specific MC-I inhibitor, at a dose of 0.1 mg/kg/h, the
uptake of 18F-BCPP-EF into the brain, especially in the frontal and temporal cortices and
striatum, was significantly facilitated just after the injection followed by faster elimination than
normal from the brain regions. The washout and metabolic rates of 18F-BCPP-EF in plasma
were rapid; only 10% of nonmetabolized 18F-BCPP-EF was detected 60 min after the injection,
which was were nearly identical with that of rotenone-treated animals. The DV values
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calculated by Logan plot graphical analysis were the highest in the occipital cortex, higher in
the striatum, intermediate in the frontal and temporal cortices and cerebellum, and lowest in
the hippocampus of young monkey. Rotenone administration resulted in a significant and
marked reduction of the binding of 18F-BCPP-EF to MC-I in the living monkey brain [16]. Taken
together, these results clearly suggested that 18F-BCPP-EF was a useful PET probe for the
quantitative imaging of MC-I activity in the living brain.
3.2. Aging effects on MC-I activity
Several hypotheses of aging have been proposed, and mitochondrial respiratory chain failures
have been implicated as factors in the aging process, which was called the “mitochondrial free
radical theory of aging” [9–13]. This theory is based on the results that (1) mitochondrial ROS
production increases with age, (2) the activity of ROS-scavenging enzymes declines with age,
(3) mutations of mitochondrial DNA (mtDNA) accumulate during aging, and (4) somatic
mtDNA mutations impair respiratory chain function, which results in a further increase in
ROS production [9–13]. Mitochondria are the main intracellular source of ROS and also the
main target of oxyradical-mediated damage, and cumulative free radical damage leads to
significant changes in brain mitochondrial function.
As described in Section 3.1, because we could confirm the capability of 18F-BCPP-EF as PET
probe for the noninvasive assessment of MC-I activity in the living brain, we further ex‐
plored to see the aging effects on MC-I activity in comparison to young and aged monkeys
under conscious condition [16]. All study procedures were identical as described in Section
3.1, except that the subjects were aged male monkeys (20–24 years old).
Aided by MRI of individual monkeys, the VOIs were set on PET images of 18F-BCPP-EF to
obtain TACs. The peak of 18F-BCPP-EF slightly shifted to a later time period between 20 and
30 min after the injection and also provided significantly lower levels than those in young
animals shown in Section 3.1. The washout and metabolic patterns of 18F-BCPP-EF in plasma
of aged monkeys were nearly identical to those in young animals. When determining the
effects of aging on 18F-BCPP-EF binding to MC-I assessed by Logan plot graphical analysis,
the data revealed significantly lower DV values of 18F-BCPP-EF in every brain region ana‐
lyzed in aged animals compared to those in young ones [16].
The remarkable finding of the present study was that 18F-BCPP-EF detected the age-related
reduction of MC-I activity in the living brain of monkey under conscious conditions with
PET (Figure 3). It was of interest that the activity of complexes I and IV decreased with age in
the brain of humans [43], whereas that of complexes II, III, and V remained mostly un‐
changed [44]. Because all these findings described above were obtained by the in vitro
assessments of dissected organ samples, the present data are the first to demonstrate the
alterations of MC-I activity in the living brain of a nonhuman primate by a noninvasive method
using 18F-BCPP-EF and PET [16].
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Figure 3. MRI and PET images of 18F-BCPP-EF in young and aged monkeys (M. mulatta). PET scans were acquired for
91 min after 18F-BCPP-EF injection with sequential arterial blood sampling. The binding of 18F-BCPP-EF to MC-I was
calculated using Logan graphical analysis with metabolite-corrected plasma input.
4. Effects of Aβ deposition on AChR and MC-I
Hallmark pathologies of AD have been assumed to the formation of extracellular aggrega‐
tion of Aβ protein (senile plaques) [19] and intraneuronal aggregation of phosphorylated tau
protein (neurofibrillary tangle) [20], pathogenic microglial activation [45], and oxidative stress
reactions [13]. Furthermore, recent reports suggested that nondeposited and nonfibrillar
assemblies of Aβ peptides are considered to play a primary role in AD, which might be
precursors in fibrillogenesis to mediate the neurotoxicity, including oxidative stress in AD [46].
This session discusses the effects of Aβ-related pathological changes on nAChR binding [36]
and also on MC-I activity [17] assessed in aged monkey brain using animal PET.
4.1. Aging effects on Aβ deposition and neuroinflammation
For the quantitative measurements of Aβ deposition in the living brain, 11C-PIB was synthe‐
sized by N-methylation of nor-compound N-desmethyl-PIB with 11C-methyl triflate (Figure
1A) [47]. For the assessment of neuroinflammation, 11C-DPA-713 was synthesized by N-
methylation of nor-compound N-desmethyl-DPA with 11C-methyl triflate (Figure 1B) [48]. PET
measurements with these two PET probes were conducted under conscious state as descri‐
bed in Section 2.2. For the analysis of 11C-PIB uptake, standard uptake value (SUV) images
were created, and the VOIs were set on each SUV images with the aid of MRI. For the analysis
of 11C-DPA-713 uptake, SUV images were created, and VOIs were set on each SUV images.
We had previously found that some, but not all, of aged monkeys exhibited higher 11C-PIB
uptake than young ones, suggesting Aβ deposition even in the brain of monkey [49]. Although
the SUVs of 11C-PIB were slightly high in the striatal regions, hippocampus, parietal cortex,
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and thalamus in aged monkeys, it was reported that aged monkeys did not reveal as high Aβ
deposition as determined in AD patients [50] and also that no species besides humans has yet
shown drastic neuron loss or cognitive decline approaching clinical-grade AD in humans. The
SUVs of 11C-DPA-713 were relatively high in the striatal regions, hippocampus, temporal
cortex, and thalamus. The plot of SUV of 11C-DPA-713 against SUV of 11C-PIB revealed
significant positive correlation both in the cortical regions. When rCMRglc ratio is plotted
against SUV of 11C-DPA-713, the results provided the significant positive correlation in the
cortical regions. There results strongly suggest that the Aβ deposition as measured with 11C-
PIB induced neuroinflammation with microglial activation as determined with 11C-DPA-713
as well as 18F-FDG (Figure 4).
Figure 4. PET/MRI fusion images of 11C-PIB, 11C-DPA-713, and 18F-BCPP-EF uptake in the brains of aged monkeys (M.
mulatta). 18F-BCPP-EF brain imaging was performed in monkey 1 with the highest binding of all 20 animals in the
conscious state and in monkey 2 with the lowest binding.
4.2. Effects of Aβ deposition on nAChR binding
Postmortem studies of human brains have suggested that a deficit of α7-nAChR is related to
AD, dementia with Lewy bodies, and schizophrenia [32]. Aβ has a high affinity to α7-nAChR
upon being enriched in basal forebrain areas, and initial Aβ deposition in early AD overlaps
with α7-nAChR expression in these regions [51]. α7-nAChR facilitates binding, internaliza‐
tion, and accumulation of Aβ1–42 and may result in the selective vulnerability of specific cells
expressing α7-nAChR [52]. Oligomers of Aβ disrupt synaptic plasticity and cognitive function
when administered at nanomolar range concentration through the modulation of NMDA
receptor function to depress NMDA-evoked currents [53, 54].
To assess the effect of Aβ deposition on α7-nAChR function, the correlation between 11C-PIB
uptake and 11C-(R)-MeQAA was analyzed [36]. As described in Section 2.2, all regions, except
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the occipital cortex, revealed no significant differences in the BPND values of 11C-(R)-MeQAA
in the brains of aged and young animals. However, of interest, when the BPND values of 11C-(R)-
MeQAA are plotted against the SUVR of 11C-PIB in the corresponding VOIs of aged animals,
the results indicated a significant positive correlation between them (Figure 5). The α7-nAChR
had been assumed to decrease with the aging process; however, the data seem to be contro‐
versial because of the dose-dependent interaction aspects between of Aβ and α7-nAChR. In
young and normal conditions, there is an equilibrium between production and elimination of
Aβ, which maintains Aβ in a steady state to perform physiologic roles by the interaction
with α7-nAChR; thus, low (on the order of picomolar) concentrations of Aβ1–42 may play a role
in modulating synaptic plasticity and enhancing cognitive function in mice via interaction
with α7-nAChR, probably in presynaptic neurons [55]. In aging with pathologic conditions,
the balance between Aβ formation and clearance is impaired, which leads to Aβ accumula‐
tion and α7-nAChR deficit as observed in postmortem brains of AD patients [32]. These results
suggest that α7-nAChR-Aβ interaction has dual effects on brain function following aging or
injury as well as preserving physiologic roles, causing the controversial results in the aging
effects on the α7-nAChR level. One previous study clearly demonstrated the significant
reduction of α7-nAChR level in neurons and also Aβ-induced up-regulation of α7-nAChR on
astrocytes in postmortem AD brain compared to that in age-matched control [56]. α7-nAChR
may be chronically inactivated in an antagonistic fashion through prolonged interaction with
increased levels (on the order of nanomolar) of Aβ, resulting in the up-regulation of α7-nAChR.
Figure 5. PET/MRI fusion images of 11C-PIB, 18F-BCPP-EF, and 11C-(R)-MeQAA in the brains of aged monkeys (M. mu‐
latta). PET images of an aged monkey with the lowest and highest 11C-PIB uptake are shown along with 18F-BCPP-EF
and 11C-(R)-MeQAA.
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4.3. Effects of Aβ deposition on MC-I activity
As shown in Section 3.2, 18F-BCPP-EF binding to MC-I in each brain region indicated much
larger variation (CV=25.1%) in aged animals than in young ones (7.4%) [16]. Since we had
previously found that some of the aged monkeys exhibited high 11C-PIB uptake, suggesting
Aβ deposition in the brain [49], the effects of Aβ deposition level assessed in Section 4.1 on
MC-I activity evaluated in Section 3.2 were determined. When the 18F-BCPP-EF binding is
plotted against the 11C-PIB uptake in the corresponding VOIs of all animals, the results
indicated a significant reversal correlation (Figure 4). In contrast, no significant relationships
were observed in the plot of rCMRglc measured using 18F-FDG against 11C-PIB uptake in the
cerebral cortical regions [17]. There results strongly suggest that the Aβ deposition as measured
with 11C-PIB induced neuroinflammation with microglial activation as determined with 11C-
DPA-713 as well as 18F-FDG. Apart from developed cells such as neurons, activated inflam‐
matory cells produce lactate from glucose, known as the Warburg effect [57] or aerobic
glycolysis, accounting for only approximately 5% glucose utilization in oxidative phosphor‐
ylation. Because activated inflammatory cells exclusively produce ATP through enhanced
glycolysis with a low contribution of the electron transport system, these cells need more
glucose to survive than normal neuronal and glial tissues, resulting in the higher 18F-FDG
uptake in the neurodegenerative damaged regions. The present results demonstrated that 18F-
BCPP-EF could be used to image MC-I activity specifically as well as to detect impaired MC-
I activity correlated to Aβ deposition in the living brain of monkeys.
5. Conclusions
In this chapter, the effects of Aβ deposition on α7-nAChR binding, TSPO activity, an estab‐
lished marker of microglial activation, and rCMRglc were assessed simultaneously with MC-
I activity. PET using 18F-FDG is a well-established technique for the quantitative imaging of
brain function as rCMRglc in the living brain. However, the unexpectedly high uptake of 18F-
FDG in damaged brain regions suggested that 18F-FDG was taken up into not only normal
tissues but also inflammatory regions with microglial activation, which hampers the accu‐
rate diagnosis of brain function using 18F-FDG. Neuroinflammation has recently emerged in
several neurodegenerative diseases, including schizophrenia, depression, autism, PD, and AD.
PET measurements of MC-I activity using 18F-BCPP-EF will be a superior diagnostic, prog‐
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